Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
Abbott Laboratories
ABTHealth technology
$210.8B
Market Cap
Shariah Analysis
Passed
Business
Cash
Liabilities
Based on AAOIFI screening standards, Abbott Laboratories appears to be Passed.
Business Activity
FYE 2024
Non-Permissible Income (<5%)1.70%
Non-Permissible
$747M
Total Income
$42.7B
Revenue Breakdown
Established Pharmaceutical Products
$5.2B
Nutritional Products
$8.4B
Diagnostic Products
$9.3B
Medical Devices
$19B
Other
$16M
Interest income
Non-Operating
$344M
Non-Compliant: $344M
Net foreign exchange (gain) loss
Non-Operating
$27M
Non-Compliant: $27M
Other (income) expense, net
Non-Operating
$376M
Non-Compliant: $376M
Financial Screening
FYE 2024
Cash (<30%)4.14%
Non-Shariah Cash Items
Cash And Cash Equivalents$7.6B
Other Short Term Investments$351M
Liabilities (<30%)7.81%
Non-Shariah Liabilities
Long Term Debt$12.6B
Long Term Capital Lease Obligation$896M
Current Debt$1.5B
Market Data
Exchange
NYSE
CurrencyUSD
CountryUnited States
Last Updated2025-12-22
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
NYSE
